This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fernández-Torres, B.
Right arrow Articles by Guarro, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fernández-Torres, B.
Right arrow Articles by Guarro, J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2003, p. 5209-5211, Vol. 41, No. 11
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.11.5209-5211.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of the New Antifungal Drug Eberconazole and Three Other Topical Agents against 200 Strains of Dermatophytes

Belkys Fernández-Torres, Isabel Inza, and Josep Guarro*

Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, 43201 Reus, Spain

Received 21 May 2003/ Returned for modification 4 July 2003/ Accepted 20 August 2003

We have compared the in vitro activity of the new antifungal drug eberconazole with those of three other topical antifungal agents, clotrimazole, ketoconazole, and miconazole, against 200 strains of dermatophytes. MICs were determined by a microdilution method with optimal conditions determined in a previous study (an inoculum of 104 CFU/ml, an incubation temperature of 28°C, an incubation period of 7 days, and a MIC endpoint of 100% inhibition of growth). In general, the four drugs tested showed low MICs. However, eberconazole was more active (P < 0.05) than the other three drugs against the majority of the species tested. Eberconazole represents an advantageous alternative for dermatophytoses where a topical therapy is required.

* Corresponding author. Mailing address: Unitat de Microbiologia, Facultat de Medicina, Universitat Rovira i Virgili, Carrer Sant Llorenç, 21, 43201 Reus, Spain. Phone: 34-977-759359. Fax: 34-977-759322. E-mail: umb{at}astor.urv.es.

Journal of Clinical Microbiology, November 2003, p. 5209-5211, Vol. 41, No. 11
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.11.5209-5211.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Frealle, E., Rodrigue, M., Gantois, N., Aliouat, C.-M., Delaporte, E., Camus, D., Dei-Cas, E., Kauffmann-Lacroix, C., Guillot, J., Delhaes, L. (2007). Phylogenetic analysis of Trichophyton mentagrophytes human and animal isolates based on MnSOD and ITS sequence comparison. Microbiology 153: 3466-3477 [Abstract] [Full Text]  
  • Yu, L., Zhang, W., Wang, L., Yang, J., Liu, T., Peng, J., Leng, W., Chen, L., Li, R., Jin, Q. (2007). Transcriptional Profiles of the Response to Ketoconazole and Amphotericin B in Trichophyton rubrum. Antimicrob. Agents Chemother. 51: 144-153 [Abstract] [Full Text]  
  • Trilles, L., Fernandez-Torres, B., dos Santos Lazera, M., Wanke, B., de Oliveira Schubach, A., de Almeida Paes, R., Inza, I., Guarro, J. (2005). In Vitro Antifungal Susceptibilities of Sporothrix schenckii in Two Growth Phases. Antimicrob. Agents Chemother. 49: 3952-3954 [Abstract] [Full Text]  
  • Fernandez-Torres, B., Inza, I., Guarro, J. (2005). Evaluation of Disk Diffusion Method for Determining Eberconazole Susceptibility of Dermatophytes and Influence of Culture Medium. Antimicrob. Agents Chemother. 49: 2116-2118 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»